NCT06823050View on ClinicalTrials.gov

A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC

Not yet recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

March 1, 2026

Study Completion Date

February 28, 2028

Conditions

Hepatocellular Carcinoma

Trial Locations (7)

Unknown

Deng zhou People's Hospital, Dengzhou

The Second People's Hospital of Jiaozuo, Jiaozuo

Huai He Hospital of Henan University, Kaifeng

Luo Yang Central Hospital, Luoyang

First People's Hospital of Shangqiu, Shangqiu

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

Zhou Kou Central Hospital, Zhoukou

All Listed Sponsors

lead

Xuhua Duan

OTHER

NCT06823050 - A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC | Biotech Hunter | Biotech Hunter